Fibrocell Science, Inc. (NYSE MKT:FCSC), an autologous cell therapy company primarily focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs, today announced that has filed a Form 12b-25 Notification of Late Filing with the U.S. Securities and Exchange Commission allowing for a five day extension in its quarterly filing of Form 10-Q for the quarter ended March 31, 2014.
Help employers find you! Check out all the jobs and post your resume.
